We recently compiled a list of the 12 Best Healthcare Stocks to Buy and Hold for 5 Years. DexCom, Inc. is one of them. DexCom, Inc. (NASDAQ:DXCM), a leader in continuous glucose monitoring (CGM) ...

With significant upside potential, DexCom, Inc. (NASDAQ:DXCM) secures a spot on our list of the 13 Best Quality Stocks to Buy According to Hedge Funds. On September 25, 2025, given that previous ...

Shares of DexCom (NASDAQ:DXCM) fell for the third straight session on Friday to reach the lowest level since April, even as the continuous glucose monitoring (CGM) equipment maker managed to retain ...

At the 61st annual European Association for the Study of Diabetes Conference (EASD) this week in Vienna, Austria, glucose monitoring company Dexcom introduced its new offering, the Dexcom Smart Basal, ...

Two major diabetes tech companies, Dexcom and Insulet, are making changes to their C-suites. Dexcom disclosed that the current CEO of the continuous glucose monitor maker, Kevin Sayer, will be taking ...

The company is presenting several abstracts during the five-day conference showcasing clinical and real-world evidence that support the benefits of its products. Dexcom is presenting several abstracts ...

With Jamaica’s Usain Bolt, the greatest sprinter of all time, watching, two current faces of the event scored their biggest wins yet Sunday at the World Athletics Championships in Tokyo. American ...

Dexcom, Inc, has issued a recall for G7 Apps and ONE+ Apps because of a software design error failing to alert users of unexpected sensor failures. This recall ...

Shares of DexCom Inc. DXCM shed 3.06% to $76.00 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.30% to 6,532.04 and the ...

Dexcom, a San Diego biotech company known for its continuous glucose monitoring systems, is laying off a few hundred workers as it moves its operations and manufacturing from California to Arizona.

Dexcom, the San Diego-based maker of continuous glucose monitors for diabetes patients and prediabetics, announced Wednesday that it is laying off around 350 workers, or 3% of its global workforce.